Truveta Stock / Digital HealthFounded: 2018

Truveta is an electronic health data software platform. The mission of Truveta is to improve health information accessibility across the United States in clinical care, specifically for COVID-19 cases. The company uses its medical insights to help patients and clinicians make better-informed decisions using features such as artificial intelligence, large language models, and health equity regulations. Truveta was founded by Terry Myerson in 2020 and is headquartered in Seattle, WA.

Register To Buy and Sell Shares

For more details on financing and valuation for Truveta, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Truveta’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Truveta.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Truveta investors also invested in these private companies


Management Team

Terry Myerson
Co-Founder & Chief Executive Officer
Fabien Mousseau
Chief Financial Officer
Jay Nanduri
Co-Founder & Chief Technology Officer
Deb Nielsen
Chief People Officer
Lisa Gurry
Co-Founder & Chief Growth Officer
Dave Heiner
Chief Policy Officer & General Counsel
Ryan Ahern MD
Co-Founder & Chief Medical Officer

Board Members

Wasif Rasheed
Providence Health & Services

Frequently Asked Questions About Truveta’s Stock

Can you buy Truveta’s stock?
Truveta is not publicly traded on NYSE or NASDAQ in the U.S. To buy Truveta’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Truveta’s stock?
Yes, you can sell stock of a private company like Truveta. Forge can help you sell your Truveta stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Truveta’s stock price?
Truveta is a privately held company and therefore does not have a public stock price. However, you may access Truveta’s private market stock price with Forge Data.
What is Truveta’s stock ticker symbol?
Truveta does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

CDC awards Truveta a real-world data contract to study COVID, maternal health, and pediatric care
Truveta was awarded a significant contract to work on public health concerns such as COVID-19.
Truveta Research on increased speech delays in children during the pandemic published in JAMA Pediatrics
Today Truveta announced new research published in JAMA Pediatrics exploring the incidence of first-time speech delays in children under the age of 5 prior to and during the pandemic. The research found a significant increase in the rate of children under the age of 5 being diagnosed with first-time speech delays since July 2020.
Truveta welcomes Patrick Caubel, Pfizer Chief Safety Officer, to its Board of Directors
Truveta, the company with a mission of saving lives with data, welcomes its first member from the life science industry to its Board of Directors. The Truveta Board of Directors ensures the data and analytics company is operating in pursuit of its mission, providing strategic, scientific, and operational direction. Today, Truveta welcomes Dr. Patrick Caubel as an independent board member. He has more than 25 years of experience in the life science industry, leading pharmacovigilance and epidemiology teams at Pfizer, Sanofi-Genzyme, Sanofi-Pasteur, and Johnson & Johnson.
Updated on: Jun 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.